Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez)

  • Clinical Trial Report
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–82, 1987

    Article  CAS  PubMed  Google Scholar 

  2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–92., 2001

    Article  CAS  PubMed  Google Scholar 

  3. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36, 2007

    Article  CAS  PubMed  Google Scholar 

  4. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 25:abstract 512, 2007

  5. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. N Engl J Med 354:809–820, 2006

    Article  CAS  PubMed  Google Scholar 

  6. Nahta R, Yu D, Hung MC, et al: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–80, 2006

    Article  CAS  PubMed  Google Scholar 

  7. Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628–38, 2007

    Article  CAS  PubMed  Google Scholar 

  8. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–43, 2006

    Article  CAS  PubMed  Google Scholar 

  9. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630–9, 2006

    Article  CAS  PubMed  Google Scholar 

  10. Johnston S, Trudeau M, Kaufman B, et al: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066–72, 2008

    Article  CAS  PubMed  Google Scholar 

  11. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–30, 2010

    Article  CAS  PubMed  Google Scholar 

  12. Andre F, Mazouni C, Liedtke C, et al: HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat, 2007

  13. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23:3676–3685, 2005

    Article  CAS  PubMed  Google Scholar 

  14. Mohsin SK, Weiss HL, Gutierrez MC, et al: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460–8, 2005

    Article  CAS  PubMed  Google Scholar 

  15. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41–8, 2005

    Article  PubMed  Google Scholar 

Download references

Disclosure

Antonio C. Wolff is a member of the ALTTO trial executive committee and is at the Breast Cancer Program of The Johns Hopkins Kimmel Comprehensive Cancer Center in Baltimore, MD. He has received research grant support from Genentech to The Johns Hopkins University School of Medicine.

Author information

Authors and Affiliations

  1. Johns Hopkins Hospital, Baltimore, MD, USA

    Antonio C. Wolff

Authors
  1. Antonio C. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio C. Wolff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolff, A.C. Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez). Curr Breast Cancer Rep 3, 1–3 (2011). https://doi.org/10.1007/s12609-010-0032-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-010-0032-2

Keywords

Search

Navigation